Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

DMK Pharmaceuticals Corporation

Company price
None USD 0.00(0%)
Last update at 2024-09-11T10:45:46.869027Z
Market Cap
6.81M

Momentum Score

…

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
3.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
3.62M
Revenue Per Share
1.03
Gross Profit TTM
-1.43M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
5388.72%
Diluted EPS TTM
-5.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -26.20M -34.60M -49.39M -29.30M
Net income -26.48M -45.83M -49.39M -29.31M
Selling general administrative 13.25M 16.14M 30.58M 25.29M
Gross profit -1.43M -4.66M 1.63M 6.64M
Reconciled depreciation 1.48M 1.44M 3.61M 2.94M
Ebit -25.06M -32.07M -31.68M -29.35M
Operating income -25.06M -32.07M -37.23M -29.03M
Interest expense - 0.01M 0.16M 0.12M
Tax provision 0.00M 0.00M 0.00M 0.01M
Interest income 0.04M - - 0.18M
Net interest income 0.04M -0.01M -0.16M 0.05M
Income tax expense 0.00M 0.00M 0.00M 0.01M
Total revenue 4.76M 2.21M 16.53M 22.11M
Total operating expenses 29.82M 34.28M 53.76M 51.14M
Cost of revenue 6.19M 6.87M 14.89M 15.48M
Total other income expense net -1.18M -2.52M -12.00M -0.32M
Discontinued operations -0.28M -11.23M -13.54M -13.54M
Net income from continuing ops -26.20M -34.60M -49.39M -29.31M
Net income applicable to common shares -26.48M -45.83M -49.39M -27.51M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.93M 38.30M 30.87M 47.84M
Intangible assets - - 6.29M 11.13M
Other current assets 4.88M 4.57M 3.03M 0.00M
Total liab 11.74M 12.42M 27.37M 11.80M
Total stockholder equity -0.81M 25.88M 3.50M 36.04M
Other current liab 1.30M 1.78M 12.81M 0.12M
Common stock 0.02M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M
Retained earnings -304.56M -278.09M -229.91M -180.52M
Other liab 0.19M 0.85M 5.86M 3.95M
Good will - - 0.87M 7.64M
Other assets 0.05M 0.11M 14.88M 1.65M
Cash 1.08M 23.22M 6.86M 8.81M
Total current liabilities 11.40M 11.22M 19.93M 9.41M
Short long term debt - - 4.37M 2.15M
Property plant equipment 1.61M 2.99M 3.47M 13.54M
Total current assets 9.27M 35.20M 12.52M 13.88M
Net tangible assets -0.81M 25.88M 3.50M 14.23M
Net receivables 1.09M 5.90M 0.24M 1.88M
Long term debt - - 0.89M -
Inventory 1.24M 0.42M 1.23M 2.06M
Accounts payable 7.94M 3.75M 1.78M 4.27M
Non currrent assets other 0.05M 0.11M 0.05M 1.60M
Non current assets total 1.66M 3.09M 18.34M 33.96M
Capital lease obligations 0.34M 0.69M 1.60M 1.93M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 3.48M 0.28M -0.95M -2.87M
Change to liabilities 3.29M 1.81M -0.34M 0.48M
Total cashflows from investing activities 3.48M 0.28M -0.95M -2.87M
Net borrowings - 1.77M 3.19M -0.50M
Total cash from financing activities 0.28M 53.94M 19.89M 12.29M
Change to operating activities -3.57M -11.80M 8.76M -0.37M
Net income -26.48M -45.83M -49.39M -27.51M
Change in cash -22.14M 16.50M -1.67M -10.46M
Begin period cash flow 23.25M 6.75M 8.81M 19.27M
End period cash flow 1.11M 23.25M 6.86M 8.81M
Total cash from operating activities -25.91M -37.72M -20.62M -19.89M
Issuance of capital stock 0.30M 51.75M 18.23M 12.79M
Depreciation 1.48M 1.44M 2.33M 2.74M
Other cashflows from investing activities 0.07M 0.10M -0.25M -0.25M
Change to inventory -0.82M -0.24M -1.77M 0.02M
Change to account receivables -0.24M -0.57M 0.32M -0.75M
Other cashflows from financing activities -0.01M -5.43M -1.53M -1.01M
Change to netincome 0.43M 17.47M 19.47M 5.30M
Capital expenditures 0.68M 1.22M 0.45M 2.87M
Change in working capital -1.34M -10.80M 5.13M -0.62M
Stock based compensation -0.34M 1.98M 4.42M 5.87M
Other non cash items 1.26M 6.21M 0.84M 0.02M
Free cash flow -26.58M -39.01M -21.85M -22.75M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

DMK Pharmaceuticals Corporation

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

11682 El Camino Real, San Diego, CA, United States, 92130

858 997 2400

11

Name Title Year Born
Mr. Seth Abraham Cohen Chief Financial Officer 1963
Mr. John W. Dorbin Jr. General Counsel Corporate Secretary 1971
Mr. Eddie Wabern Glover Chief Executive Officer of US Compounding Inc 1950

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…